125 related articles for article (PubMed ID: 26046768)
1. Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
Oliveira-Carvalho V; Ferreira LR; Bocchi EA
J Appl Toxicol; 2015 Sep; 35(9):1071-2. PubMed ID: 26046768
[No Abstract] [Full Text] [Related]
2. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
Rigaud VO; Ferreira LR; Ayub-Ferreira SM; Ávila MS; Brandão SM; Cruz FD; Santos MH; Cruz CB; Alves MS; Issa VS; Guimarães GV; Cunha-Neto E; Bocchi EA
Oncotarget; 2017 Jan; 8(4):6994-7002. PubMed ID: 28052002
[TBL] [Abstract][Full Text] [Related]
3. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
[TBL] [Abstract][Full Text] [Related]
4. Paving the Route to Plasma miR-208a-3p as an Acute Cardiac Injury Biomarker: Preclinical Rat Data Supports Its Use in Drug Safety Assessment.
Glineur SF; De Ron P; Hanon E; Valentin JP; Dremier S; Nogueira da Costa A
Toxicol Sci; 2016 Jan; 149(1):89-97. PubMed ID: 26454886
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Siegel ER; Wei J; Stone A; Carter W; Beggs ML; Owen A; Klimberg VS
PLoS One; 2016; 11(8):e0160224. PubMed ID: 27490685
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity.
Holmgren G; Synnergren J; Andersson CX; Lindahl A; Sartipy P
Toxicol In Vitro; 2016 Aug; 34():26-34. PubMed ID: 27033315
[TBL] [Abstract][Full Text] [Related]
7. Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats.
Nishimura Y; Kondo C; Morikawa Y; Tonomura Y; Torii M; Yamate J; Uehara T
J Appl Toxicol; 2015 Feb; 35(2):173-80. PubMed ID: 25092230
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of Doppler echocardiography, tissue Doppler imaging and biomarkers measurement for the detection of doxorubicin-induced cardiotoxicity in dogs: A pilot study.
Gallay-Lepoutre J; Bélanger MC; Nadeau ME
Res Vet Sci; 2016 Apr; 105():153-9. PubMed ID: 27033925
[TBL] [Abstract][Full Text] [Related]
9. Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer.
Qin X; Chang F; Wang Z; Jiang W
Cancer Biomark; 2018; 23(4):473-484. PubMed ID: 30452398
[TBL] [Abstract][Full Text] [Related]
10. Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients.
Todorova VK; Makhoul I; Wei J; Klimberg VS
Ann Clin Lab Sci; 2017 Mar; 47(2):115-119. PubMed ID: 28442511
[TBL] [Abstract][Full Text] [Related]
11. Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients.
Ruggeri C; Gioffré S; Achilli F; Colombo GI; D'Alessandra Y
Heart Fail Rev; 2018 Jan; 23(1):109-122. PubMed ID: 28944400
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin-induced cardiotoxicity.
Beaumier A; Robinson SR; Robinson N; Lopez KE; Meola DM; Barber LG; Bulmer BJ; Calvalido J; Rush JE; Yeri A; Das S; Yang VK
J Vet Intern Med; 2020 May; 34(3):1260-1271. PubMed ID: 32255536
[TBL] [Abstract][Full Text] [Related]
13. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
Herman EH; Lipshultz SE; Rifai N; Zhang J; Papoian T; Yu ZX; Takeda K; Ferrans VJ
Cancer Res; 1998 Jan; 58(2):195-7. PubMed ID: 9443390
[TBL] [Abstract][Full Text] [Related]
14. [Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients].
Huang WB; Yao GY; Liu MF; Chen RT; Chen LJ; Dong JY; Gu F; Guo ZZ; Ye CS
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(6):1047-50. PubMed ID: 21690066
[TBL] [Abstract][Full Text] [Related]
15. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
[TBL] [Abstract][Full Text] [Related]
16. Baicalein alleviates doxorubicin-induced cardiotoxicity via suppression of myocardial oxidative stress and apoptosis in mice.
Sahu BD; Kumar JM; Kuncha M; Borkar RM; Srinivas R; Sistla R
Life Sci; 2016 Jan; 144():8-18. PubMed ID: 26606860
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin.
Jones RL; Berry GJ; Rubens RD; Miles DW
Lancet Oncol; 2004 Sep; 5(9):575-7. PubMed ID: 15337488
[No Abstract] [Full Text] [Related]
18. Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy.
Tikoo K; Sane MS; Gupta C
Toxicol Appl Pharmacol; 2011 Mar; 251(3):191-200. PubMed ID: 21194538
[TBL] [Abstract][Full Text] [Related]
19. Effect of methimazole treatment on doxorubicin-induced cardiotoxicity in mice.
Osman AM; Nemnem MM; Abou-Bakr AA; Nassier OA; Khayyal MT
Food Chem Toxicol; 2009 Oct; 47(10):2425-30. PubMed ID: 19577608
[TBL] [Abstract][Full Text] [Related]
20. microRNA miR-133a as a Biomarker for Doxorubicin-Induced Cardiotoxicity in Women with Breast Cancer: A Signaling Pathway Investigation.
Alves MT; da Conceição IMCA; de Oliveira AN; Oliveira HHM; Soares CE; de Paula Sabino A; Silva LM; Simões R; Luizon MR; Gomes KB
Cardiovasc Toxicol; 2022 Jul; 22(7):655-662. PubMed ID: 35524907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
